Neuland Laboratories Limited
NSE: NEULANDLAB BSE: NEULANDLAB
NSE
13,136.00
315.00 (2.46%)
Prev Close
12821
Open Price
12886
Volume
53,273
Today Low / High
12794 / 13300
52 WK Low / High
5540.1 / 18100
Range
12,479 - 13,793
BSE
13,116.20
291.85 (2.28%)
Prev Close
12824.35
Open Price
12899
Volume
2,346
Today Low / High
12797.55 / 13279.45
52 WK Low / High
5557 / 18089.55
Range
12,460 - 13,772
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 13136 (target range: 12,479 - 13,793), reflecting a change of 315 (2.45691%). On the BSE, it is listed at 13116.2 (target range: 12,460 - 13,772), showing a change of 291.85 (2.27575%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
21 Apr
12,886.00
1.94%
17 Apr
12,650.00
1.35%
16 Apr
12,660.00
0.70%
15 Apr
12,000.00
5.50%
11 Apr
11,144.35
5.47%
09 Apr
11,016.00
-0.51%
08 Apr
11,073.10
1.00%
07 Apr
10,492.00
4.48%
04 Apr
12,026.75
-4.89%
03 Apr
11,650.00
3.46%
02 Apr
11,485.75
0.72%
01 Apr
11,980.00
-4.14%
28 Mar
12,037.00
0.29%
27 Mar
11,210.00
7.66%
26 Mar
11,915.00
-5.40%
25 Mar
12,009.90
-0.79%
24 Mar
11,900.00
0.08%
Neuland Laboratories Limited Graph
Neuland Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Neuland Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 13,136.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 13,116.20 | 13,247.36 | 11,922.63 - 14,572.10 |
| 13,378.52 | 10,702.82 - 16,054.23 | ||
| 13,509.69 | 9,456.78 - 17,562.59 | ||
| Bearish Scenario | 13,116.20 | 12,985.04 | 11,686.53 - 14,283.54 |
| 12,853.88 | 10,283.10 - 15,424.65 | ||
| 12,722.71 | 8,905.90 - 16,539.53 |
Overview of Neuland Laboratories Limited
ISIN
INE794A01010
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
48,969
Market Cap
168,533,566,400
Last Dividend
14
Official Website
IPO Date
2008-10-13
DCF Diff
9,107.81
DCF
4,028
Financial Ratios Every Investor Needs
Stock Dividend of NEULANDLAB
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-07-12 | July 12, 24 | 14 | 14 | 2024-07-12 | 2024-08-30 | |
| 2023-07-11 | July 11, 23 | 10 | 10 | 2023-07-11 | 2023-08-26 | |
| 2022-07-14 | July 14, 22 | 5 | 5 | 2022-07-15 | 2022-09-01 | |
| 2021-06-29 | June 29, 21 | 3 | 3 | 2021-06-30 | 2021-08-03 | |
| 2020-11-10 | November 10, 20 | 2 | 2 | 2020-11-11 | 2020-11-27 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,558.58 Cr | 733.80 Cr | 824.78 Cr | 0.5292 | 43.50 Cr | 30.92 Cr | 531.81 Cr | 300.08 Cr | 233.89 | 474.82 Cr | 0.1925 |
| 2023-03-31 | 1,160.90 Cr | 613.79 Cr | 547.11 Cr | 0.4713 | 27.76 Cr | 29.89 Cr | 234.34 Cr | 163.52 Cr | 127.45 | 279.18 Cr | 0.1409 |
| 2022-03-31 | 923.33 Cr | 553.50 Cr | 369.83 Cr | 0.4005 | 0.36 Cr | 15.69 Cr | 96.09 Cr | 63.82 Cr | 49.74 | 140.40 Cr | 0.0691 |
| 2021-03-31 | 918.18 Cr | 554.72 Cr | 363.46 Cr | 0.3958 | 21.07 Cr | 13.49 Cr | 109.63 Cr | 80.63 Cr | 62.85 | 162.91 Cr | 0.0878 |
| 2020-03-31 | 764.03 Cr | 477.79 Cr | 286.23 Cr | 0.3746 | 0.00 Cr | 14.80 Cr | 73.60 Cr | 16.21 Cr | 12.63 | 100.36 Cr | 0.0212 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 87.58 Cr | 1,832.56 Cr | 549.86 Cr | 1,282.7048 Cr | 95.39 Cr | 7.81 Cr | 350.42 Cr | 568.61 Cr | 81.17 Cr | 0.00 Cr | 13.76 Cr | 427.6832 Cr |
| 2023-03-31 | 45.42 Cr | 1,579.76 Cr | 585.67 Cr | 994.0965 Cr | 128.45 Cr | 83.03 Cr | 279.23 Cr | 498.00 Cr | 136.56 Cr | 0.00 Cr | 0.00 Cr | 438.9570 Cr |
| 2022-03-31 | 5.09 Cr | 1,383.49 Cr | 542.99 Cr | 840.5008 Cr | 240.53 Cr | 235.44 Cr | 265.21 Cr | 486.58 Cr | 0.00 Cr | 0.00 Cr | 0.50 Cr | 363.1566 Cr |
| 2021-03-31 | 2.44 Cr | 1,324.79 Cr | 538.33 Cr | 786.4577 Cr | 182.29 Cr | 179.86 Cr | 247.61 Cr | 431.23 Cr | 63.61 Cr | 0.03 Cr | -7.68 Cr | 368.5109 Cr |
| 2020-03-31 | 11.20 Cr | 1,230.98 Cr | 521.02 Cr | 709.9577 Cr | 263.73 Cr | 252.53 Cr | 219.55 Cr | 365.22 Cr | 21.67 Cr | 20.28 Cr | -3.84 Cr | 357.6337 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 261.1767 Cr | -149.6868 Cr | -69.2818 Cr | 117.5069 Cr | 42.1595 Cr | 87.5754 Cr | -143.6698 Cr | 300.0789 Cr | -39.4402 Cr | -12.8299 Cr | -71.1885 Cr |
| 2023-03-31 | 237.2119 Cr | -61.4985 Cr | -135.7956 Cr | 171.0834 Cr | 40.3245 Cr | 45.4159 Cr | -66.1285 Cr | 215.2129 Cr | -113.5815 Cr | -6.4149 Cr | -14.0233 Cr |
| 2022-03-31 | 60.3888 Cr | -95.5163 Cr | 37.7215 Cr | -37.2972 Cr | 2.6558 Cr | 5.0914 Cr | -97.6860 Cr | 82.1625 Cr | 20.3341 Cr | -3.8490 Cr | -17.6024 Cr |
| 2021-03-31 | 189.3617 Cr | -84.4237 Cr | -113.6604 Cr | 83.9647 Cr | -8.7679 Cr | 2.4356 Cr | -105.3970 Cr | 105.3335 Cr | -89.6629 Cr | -2.5660 Cr | -28.0603 Cr |
| 2020-03-31 | 57.3412 Cr | -48.6796 Cr | -5.4804 Cr | 8.5444 Cr | 3.2658 Cr | 11.2035 Cr | -48.7968 Cr | 52.9225 Cr | 7.4821 Cr | -4.9495 Cr | -26.8932 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 398.03 Cr | 205.72 Cr | 192.31 Cr | 0.4831 | 70.30 Cr | 101.59 Cr | 79.18 | 146.28 Cr | 0.2552 |
| 2024-09-30 | 310.84 Cr | 159.76 Cr | 151.09 Cr | 0.4861 | 46.15 Cr | 32.84 Cr | 25.60 | 66.56 Cr | 0.1057 |
| 2024-06-30 | 439.60 Cr | 302.46 Cr | 137.15 Cr | 0.3120 | 107.08 Cr | 97.87 Cr | 76.28 | 148.79 Cr | 0.2226 |
| 2024-03-31 | 385.01 Cr | 180.02 Cr | 204.99 Cr | 0.5324 | 90.45 Cr | 67.56 Cr | 52.66 | 109.35 Cr | 0.1755 |
| 2023-12-31 | 392.83 Cr | 178.59 Cr | 214.24 Cr | 0.5454 | 106.12 Cr | 81.39 Cr | 63.44 | 123.37 Cr | 0.2072 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 72.47 Cr | 125.03 Cr | 197.51 Cr | 0.00 Cr | 386.46 Cr | 966.48 Cr | 669.99 Cr | 1,943.80 Cr | 548.59 Cr |
| 2024-06-30 | -87.58 Cr | 175.15 Cr | 87.58 Cr | 0.00 Cr | 0.00 Cr | 87.58 Cr | 0.00 Cr | 0.00 Cr | -1,282.70 Cr |
| 2024-03-31 | 87.58 Cr | 15.01 Cr | 102.59 Cr | 375.99 Cr | 350.42 Cr | 921.08 Cr | 568.61 Cr | 1,832.56 Cr | 549.86 Cr |
| 2023-12-31 | -136.54 Cr | 273.09 Cr | 136.54 Cr | 0.00 Cr | 0.00 Cr | 136.54 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 125.01 Cr | 16.72 Cr | 141.72 Cr | 324.90 Cr | 296.28 Cr | 833.83 Cr | 511.73 Cr | 1,665.06 Cr | 532.28 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 97.87 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 67.56 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 81.39 Cr | 30.29 Cr | 0.00 Cr | 0.00 Cr | 30.29 Cr | 166.83 Cr | 136.54 Cr | 0.00 Cr | 30.29 Cr |
| 2023-09-30 | 89.25 Cr | 29.02 Cr | 0.00 Cr | 0.00 Cr | 29.02 Cr | 136.54 Cr | 107.53 Cr | 0.00 Cr | 29.02 Cr |
| 2023-06-30 | 61.88 Cr | 27.17 Cr | 0.00 Cr | 0.00 Cr | 27.17 Cr | 72.70 Cr | 45.53 Cr | 0.00 Cr | 27.17 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2014-08-13 | August 13, 14 | 523:500 |
| 2012-03-21 | March 21, 12 | 289:250 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,619,911,900.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Executive Chairman & Chief Promoter and Member of Scientific Advisory Board
Dr. Davuluri Rama Mohan Rao
Gender: Not Specified
Year Born: 1944
Vice Chairman & Chief Executive Officer
Mr. Davuluri Sucheth Rao
Gender: male
Year Born: 1975
Chief Financial Officer
Mr. Abhijit Majumdar
Gender: male
Year Born:
Chief Scientific Officer & Member of Scientific Advisory Board
Dr. Sharadsrikar Venkatesan Kotturi
Gender: Not Specified
Year Born:
Company Secretary & Compliance Officer
Ms. Sarada Bhamidipati
Gender: female
Year Born:
Chief Procurement Officer
Mr. N. Sundar
Gender: male
Year Born: 1968
Senior Vice President of Global Head Sales & BD
Mr. Sudheer Yarabolu
Gender: male
Year Born:
Chief Human Resources Officer
Mr. Hemchandra Peruvelli
Gender: male
Year Born: 1972
President of Business Development & Contract Manufacturing
Mr. Shashank Mahashabde
Gender: male
Year Born:
Vice Chairman & MD
Mr. Davuluri Saharsh Rao
Gender: male
Year Born: 1979
FAQs about Neuland Laboratories Limited
Who is the CEO of the company?
The CEO is Mr. Davuluri Sucheth Rao.
What is the current market price of the stock?
The current price is ₹13,136.00.
What is the 52-week price range?
The range is ₹5540.1-18100.
What is the market capitalization of the company?
The market capitalization is ₹16,853.36 crores.
What is the dividend yield?
The dividend yield is 0.11%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 56.20.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Neuland Laboratories Limited (ISIN: INE794A01010) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹16,853.36 crores and an average daily volume of 48,969 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹14.